Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid, likely triggered by scabies, in a hemodialysis patient with human leukocyte antigen-DQB1*03:01 [PDF]
, 2020 Arata Hibi +5 more
openalex +1 more source
American Journal of Kidney Diseases, 2015 BACKGROUND Although assessment of cardiovascular safety is mandated by regulatory agencies for the development of new drugs to treat type 2 diabetes, evaluation of their renal safety has been relatively neglected.
M. Cooper +8 more
semanticscholar +1 more source
What doesn't kill you makes you stranger: Dipeptidyl peptidase-4 (CD26) proteolysis differentially modulates the activity of many peptide hormones and cytokines generating novel cryptic bioactive ligands [PDF]
, 2019 Dipeptidyl peptidase 4 (DPP4) is an exopeptidase found either on cell surfaces where it is highly regulated in terms of its expression and surface availability (CD26) or in a free/circulating soluble constitutively available and intrinsically active form.
Aguilar-Pérez, Alexandra +13 more
core +1 more source
Association between dipeptidyl peptidase-4 inhibitors use and leptin in type 2 diabetes mellitus [PDF]
, 2021 Xin Wei +5 more
openalex +1 more source
Journal of Diabetes Investigation, 2017 The combination of dipeptidyl peptidase‐4 (DPP4) inhibitors and α‐glucosidase inhibitors (AGIs) might provide an additive or synergistic glucose‐lowering effect, as they have a complementary mode of action.
S. Min, Jeong-Hwa Yoon, S. Hahn, Y. Cho
semanticscholar +1 more source
Hepatocyte-specific HIF-1α ablation improves obesity-induced glucose intolerance by reducing first-pass GLP-1 degradation. [PDF]
, 2019 The decrease in incretin effects is an important etiologic component of type 2 diabetes with unknown mechanisms. In an attempt to understand obesity-induced changes in liver oxygen homeostasis, we found that liver HIF-1α expression was increased mainly ...
Bandyopadhyay, Guatam K +3 more
core
Comparison of cardiovascular outcomes and cardiometabolic risk factors between patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors: a meta-analysis [PDF]
, 2021 Siwen Wang +5 more
openalex +1 more source
Dipeptidyl peptidase-4 inhibitor for steroid-induced diabetes
World Journal of Diabetes, 2010 The addition of the dipeptidyl peptidase-4 (DDP-4) inhibitor has been reported to achieve greater improvements in glucose metabolism with fewer adverse events compared to increasing the metformin dose in type 2 diabetic patients. We present a patient with steroid-induced diabetes whose blood glucose levels were ameliorated by the use of the DPP-4 ...
Hidekatsu, Yanai +4 more
openaire +2 more sources
Diabetes, obesity and metabolism, 2017 To compare the efficacy and safety of the once‐weekly oral dipeptidyl peptidase‐4 (DPP‐4) inhibitor omarigliptin or once‐daily DPP‐4 inhibitor sitagliptin in patients with type 2 diabetes (T2DM) and inadequate glycaemic control on metformin.
R. Goldenberg +8 more
semanticscholar +1 more source
Journal of Pharmacological Sciences, 2019 Dipeptidyl peptidase-4 (DPP-4) inhibitors not only improve impaired glucose tolerance in diabetes, but also have pleiotropic extra-pancreatic effects such as preconditioning effect for myocardial ischemia-reperfusion injury.
Takehiro Yamaguchi +12 more
doaj +1 more source